UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of COVID-19 Pandemic on Patients with Serious Mental Illness (SMI) and Nonpsychiatric Control Subjects in Clinical Trials

Innovations in clinical neuroscience, 2024-01, Vol.21 (1-3), p.13-18

2024

Volltextzugriff (PDF)

Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]

Schizophrenia research, 2022-08, Vol.246, p.258-259

2022

Volltextzugriff (PDF)

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Schizophrenia research, 2022-01, Vol.239, p.83-91

2022

Volltextzugriff (PDF)

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2019-02, Vol.44 (3), p.598-605

2019

Volltextzugriff (PDF)

Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2019-02, Vol.44 (3), p.598

2019

Volltextzugriff (PDF)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial

International clinical psychopharmacology, 2016-03, Vol.31 (2), p.61-68

2016

Volltextzugriff (PDF)

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study

Schizophrenia research, 2016-04, Vol.172 (1-3), p.152-157

2016

Volltextzugriff (PDF)

Low-power, low-rate ultrasonic communications system transmitting axially along a cylindrical pipe using transverse waves

IEEE transactions on ultrasonics, ferroelectrics, and frequency control, 2015-10, Vol.62 (10), p.1788-1796

2015

Volltextzugriff (PDF)

Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic

Innovations in clinical neuroscience, 2021-01, Vol.18 (1-3), p.35-38

2021

Volltextzugriff (PDF)

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

International clinical psychopharmacology, 2018-03, Vol.33 (2), p.79-87

2018

Volltextzugriff (PDF)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis

International journal of clinical practice (Esher), 2017-12, Vol.71 (12), p.e13037-n/a

2017

Volltextzugriff (PDF)

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study

Journal of clinical psychopharmacology, 2014-04, Vol.34 (2), p.199-204

2014

Volltextzugriff (PDF)

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

Journal of clinical psychopharmacology, 2008-04, Vol.28 (2 Suppl 1), p.S4-S11

2008

Volltextzugriff (PDF)

Poster #S239 AZD8529, A POSITIVE ALLOSTERIC MODULATOR AT THE MGLUR2 RECEPTOR, DOES NOT IMPROVE SYMPTOMS IN SCHIZOPHRENIA: A PROOF OF PRINCIPLE STUDY

Schizophrenia research, 2014-04, Vol.153, p.S176-S176

2014

Volltextzugriff (PDF)

Stress and Coping With the COVID-19 Pandemic: A Survey of Psychiatric Patients at Clinical Trial Sites

Biological psychiatry (1969), 2021-05, Vol.89 (9), p.S158-S159

2021

Volltextzugriff (PDF)

Impact of COVID-19 Pandemic on Psychiatric Patients at Clinical Trial Sites

Innovations in clinical neuroscience, 2022-10, Vol.19 (10-12), p.24-28

2022

Volltextzugriff (PDF)

Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder

Journal of clinical pharmacology, 2024-10

2024

Volltextzugriff (PDF)

The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial

Neuropsychopharmacology (New York, N.Y.), 2023-06, Vol.48 (7), p.1052-1059

2023

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2009-04, Vol.34 (5), p.1322-1329

2009

Volltextzugriff (PDF)

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

The international journal of neuropsychopharmacology, 2010-06, Vol.13 (5), p.635-647

2010

Volltextzugriff (PDF)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

Neuropsychiatric disease and treatment, 2023-01, Vol.19, p.219-232

2023

Volltextzugriff (PDF)

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

NPJ schizophrenia, 2020-11, Vol.6 (1), p.37-37, Article 37

2020

Volltextzugriff (PDF)

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

British journal of psychiatry, 1996-05, Vol.168 (5), p.571-579

1996

Volltextzugriff (PDF)

Understanding the Radioactive Ingrowth and Decay of Naturally Occurring Radioactive Materials in the Environment: An Analysis of Produced Fluids from the Marcellus Shale

Environmental health perspectives, 2015-07, Vol.123 (7), p.689-689

2015

Volltextzugriff (PDF)

Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study

Schizophrenia research, 2019-04, Vol.206, p.291-299

2019

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

Englisch
(305)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(181)
Humans
(143)
Female
(74)
Biological And Medical Sciences
(65)
Male
(60)
Medical Sciences
(54)
Psychiatry
(53)
Animals
(44)
Adult
(43)
Middle Aged
(42)
Molecular Sequence Data
(31)
Immunology
(29)
Suicide
(27)
Social Sciences
(25)
Amino Acid Sequence
(23)
Base Sequence
(21)
Psychology
(21)
Psychology. Psychoanalysis. Psychiatry
(21)
Adolescent
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Impact of COVID-19 Pandemic on Patients with Serious Mental Illness (SMI) and Nonpsychiatric Control Subjects in Clinical Trials

Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]

Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study

Low-power, low-rate ultrasonic communications system transmitting axially along a cylindrical pipe using transverse waves

Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

Poster #S239 AZD8529, A POSITIVE ALLOSTERIC MODULATOR AT THE MGLUR2 RECEPTOR, DOES NOT IMPROVE SYMPTOMS IN SCHIZOPHRENIA: A PROOF OF PRINCIPLE STUDY

Stress and Coping With the COVID-19 Pandemic: A Survey of Psychiatric Patients at Clinical Trial Sites

Impact of COVID-19 Pandemic on Psychiatric Patients at Clinical Trial Sites

Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder

The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial

A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

Understanding the Radioactive Ingrowth and Decay of Naturally Occurring Radioactive Materials in the Environment: An Analysis of Produced Fluids from the Marcellus Shale

Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study

Suchergebnisse filtern